Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
Epitopea Ltd. has signed a license and research collaboration agreement with MSD (Merck & Co. Inc.) to identify Cryptigen tumor-specific antigens in an undisclosed solid tumor. Cryptigen TSAs are ...
Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.
Life science company Epitopea, rooted in Cambridge UK and both Montreal and Quebec in Canada, has clinched a licensing deal ...
Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a clinical stage ...
Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called ...
Life science company Epitopea, rooted in Cambridge UK and both Montreal and Quebec in Canada, has clinched a licensing deal and research collaboration with MSD that is potentially worth several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback